MOU and Heads of Terms Agreement with TRx Biosciences Ltd (formerly Biocopea)

On January 13, 2021 Oxilio reported that entered a Memorandum of Understanding with Biocopea Ltd regarding the establishment of a collaborative product development relationship (Press release, Oxilio, JAN 13, 2021, View Source [SID1234621612]). This relationship is for the application of Biocopea formulation technologies to enable differentiated pharmaceutical products based on aprepitant.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!